JMackem Co., Ltd
🇰🇷South Korea
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Oral Administration of AJH-2947 in Healthy Korean and/or Caucasian Adult Male Subjects
Phase 1
- Conditions
- Neuropathic PainPost Herpetic NeuralgiaDiabetic Neuropathies
- Interventions
- Drug: AJH-2947 400 mg (SAD)Drug: AJH-2947 300 mg (SAD)Drug: AJH-2947 400 mg (MAD)Drug: AJH-2947 200 mg (SAD)Drug: AJH-2947 100 mg (SAD)Drug: AJH-2947 800 mg (SAD)Drug: AJH-2947 200 mg (MAD)Drug: AJH-2947 600 mg (SAD)Drug: AJH-2947 600 mg (MAD)Drug: Placebo
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- JMackem Co., Ltd
- Target Recruit Count
- 68
- Registration Number
- NCT06155487
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath